Company / Cost of Revenue
Twist Bioscience Corp Cost of Revenue History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$185.6M
FY2025
5-year range
$80.6M / $185.6M
FY2021-FY2025
Trend
+3.3%
vs FY2024
Sector context
#36 of 83
Health Care
What the data says
At $186M, Twist Bioscience Corp's cost of revenue ranks #48 of 83 in the Health Care sector. Cost of Revenue has increased for 8 consecutive years, from $24M in FY2017 to $186M in FY2025.
Based on SEC 10-K filings.
$186M in FY2025 with a 5-year CAGR of +24.8%.
Increased from $155M to $186M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +15.9%
- 5-Year CAGR
- +24.8%
- 10-Year CAGR
- -
Sector benchmark
#48 of 83 in Health CareTop 57% of 83This company $185.6M Sector average $2.0B
▼
-90.8% below sector average
Key checks
Key Insights
- Twist Bioscience Corp's cost of revenue has grown for 8 consecutive years.
- 5-year CAGR of +24.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 3.3% year-over-year.
- Ranks #36 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $185.6M | +3.3% |
| FY2024 | $179.6M | +15.6% |
| FY2023 | $155.4M | +30.2% |
| FY2022 | $119.3M | +48.0% |
| FY2021 | $80.6M | +31.3% |
| FY2020 | $61.4M | +29.5% |
| FY2019 | $47.4M | +47.3% |
| FY2018 | $32.2M | +34.0% |
| FY2017 | $24.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026